title: Intramuscular inoculation of mice with the live-attenuated recombinant rabies virus TriGAS results in a transient infection of the draining lymph nodes and a robust, long-lasting protective immune response against rabies.
abstract: A single intramuscular application of the live but not UV-inactivated recombinant rabies virus (RABV) variant TriGAS in mice induces the robust and sustained production of RABV-neutralizing antibodies that correlate with long-term protection against challenge with an otherwise lethal dose of the wild-type RABV. To obtain insight into the mechanism by which live TriGAS induces long-lasting protective immunity, quantitative PCR (qPCR) analysis of muscle tissue, draining lymph nodes, spleen, spinal cord, and brain at different times after TriGAS inoculation revealed the presence of significant copy numbers of RABV-specific RNA in muscle, lymph node, and to a lesser extent, spleen for several days postinfection. Notably, no significant amounts of RABV RNA were detected in brain or spinal cord at any time after TriGAS inoculation. Differential qPCR analysis revealed that the RABV-specific RNA detected in muscle is predominantly genomic RNA, whereas RABV RNA detected in draining lymph nodes is predominantly mRNA. Comparison of genomic RNA and mRNA obtained from isolated lymph node cells showed the highest mRNA-to-genomic-RNA ratios in B cells and dendritic cells (DCs), suggesting that these cells represent the major cell population that is infected in the lymph node. Since RABV RNA declined to undetectable levels by 14 days postinoculation of TriGAS, we speculate that a transient infection of DCs with TriGAS may be highly immunostimulatory through mechanisms that enhance antigen presentation. Our results support the superior efficacy and safety of TriGAS and advocate for its utility as a vaccine.
authors.affiliation: Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
authors.forename: Keith
authors.initials: K
authors.lastname: Schutsky
authors.forename: Dana
authors.initials: D
authors.lastname: Curtis
authors.forename: Emily K
authors.initials: EK
authors.lastname: Bongiorno
authors.forename: Darryll A
authors.initials: DA
authors.lastname: Barkhouse
authors.forename: Rhonda B
authors.initials: RB
authors.lastname: Kean
authors.forename: Bernhard
authors.initials: B
authors.lastname: Dietzschold
authors.forename: D Craig
authors.initials: DC
authors.lastname: Hooper
authors.forename: Milosz
authors.initials: M
authors.lastname: Faber
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000821:virology; D001921:Brain / Q000473:pathology / Q000821:virology; D003713:Dendritic Cells / Q000821:virology; D005260:Female; D007273:Injections, Intramuscular; D008198:Lymph Nodes / Q000276:immunology / Q000473:pathology / Q000821:virology*; D051379:Mice; D009132:Muscles / Q000473:pathology / Q000821:virology; D012367:RNA, Viral / Q000032:analysis / Q000235:genetics; D011818:Rabies / Q000517:prevention & control* / Q000821:virology; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology* / Q000472:pathogenicity; D060888:Real-Time Polymerase Chain Reaction; D013116:Spinal Cord / Q000473:pathology / Q000821:virology; D013154:Spleen / Q000473:pathology / Q000821:virology; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
chemical_list: D012367:RNA, Viral; D011819:Rabies Vaccines; D014613:Vaccines, Attenuated